A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Status unconfirmed · Phase 2

Conditions studied: Hypertrophic Scar

In brief

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.

Key facts

Study ID

NCT02246465

Run by

RXi Pharmaceuticals, Corp.

People needed

40

Starts

2014-07-01

Expected to finish

2018-03-01

Last updated by the study team

2018-02-23

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults, 21-55 years of age
• General good health
• Previous surgery or injury resulting in a hypertrophic scar

You may not qualify if…

• Scars on the face or front of neck may not be included in the trial
• Use of tobacco or nicotine-containing products
• Pregnant or lactating

Where it is running

• Study site — Beverly Hills, California, United States
• Study site — Lake Worth, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — St Louis, Missouri, United States
• Study site — Huntersville, North Carolina, United States
• Study site — San Pedro Sula, Honduras

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.